AR006942A1 - Manufactura de un medicamento para inhibir una respuesta antigeno- especifica, composiciones farmaceuticas y celulas t anergicas antigeno-especificas - Google Patents

Manufactura de un medicamento para inhibir una respuesta antigeno- especifica, composiciones farmaceuticas y celulas t anergicas antigeno-especificas

Info

Publication number
AR006942A1
AR006942A1 ARP970101817A ARP970101817A AR006942A1 AR 006942 A1 AR006942 A1 AR 006942A1 AR P970101817 A ARP970101817 A AR P970101817A AR P970101817 A ARP970101817 A AR P970101817A AR 006942 A1 AR006942 A1 AR 006942A1
Authority
AR
Argentina
Prior art keywords
specific
cells
antigen
inhibit
manufacture
Prior art date
Application number
ARP970101817A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR006942A1 publication Critical patent/AR006942A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describe la Interleucina-10 para producir una población de células que son capaces de inhibir o suprimir las reacciones a los aloantígenos, porejempo, en la enfermedad injerto-versus-huésped o el rechazo de tejido. La Interleucina-10 parar educir las respuestas en la respuesta de linfocitomixta (RLM) también se describe. Puede utilizarse la IL-10 inducida exógena o endógena para la inhibición o supresión de las reacciones a los aloantígenos.Además se describe un método parafabricar un medicamento que la contiene, una composición farmacéutica y células T anérgicas antígeno-específicas.
ARP970101817A 1996-05-06 1997-05-02 Manufactura de un medicamento para inhibir una respuesta antigeno- especifica, composiciones farmaceuticas y celulas t anergicas antigeno-especificas AR006942A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/643,810 US6277635B1 (en) 1992-03-04 1996-05-06 Use of interleukin-10 to produce a population of suppressor cells

Publications (1)

Publication Number Publication Date
AR006942A1 true AR006942A1 (es) 1999-09-29

Family

ID=24582315

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970101817A AR006942A1 (es) 1996-05-06 1997-05-02 Manufactura de un medicamento para inhibir una respuesta antigeno- especifica, composiciones farmaceuticas y celulas t anergicas antigeno-especificas

Country Status (16)

Country Link
US (1) US6277635B1 (es)
EP (1) EP0906428A1 (es)
JP (1) JP2000509604A (es)
KR (1) KR20000010799A (es)
AR (1) AR006942A1 (es)
AU (1) AU2927597A (es)
BR (1) BR9709307A (es)
CA (1) CA2253803A1 (es)
CZ (1) CZ347798A3 (es)
IL (1) IL126658A0 (es)
NO (1) NO985160L (es)
NZ (1) NZ332413A (es)
PL (1) PL329732A1 (es)
SK (1) SK151898A3 (es)
WO (1) WO1997042324A1 (es)
ZA (1) ZA973815B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358506B1 (en) 1997-11-05 2002-03-19 University Of Southern California Use of cytokines and mitogens to inhibit pathological immune responses
WO1999030730A1 (en) * 1997-12-15 1999-06-24 Universite Laval Methods and compositions for improving the success of cell transplantation in a host
US6803036B1 (en) 1998-03-03 2004-10-12 University Of Southern California Use of cytokines, cells and mitogens to inhibit graft versus host disease
EP1061949B1 (en) 1998-03-03 2009-07-15 University of Southern California Cytokines and mitogens to inhibit graft-versus-host disease
WO2001016296A2 (en) * 1999-09-01 2001-03-08 University Of Southern California Use of cytokines, cells, and mitogens to inhibit graft versus host disease
GB9928193D0 (en) * 1999-11-29 2000-01-26 Univ Bristol Cell treatment method
WO2001077299A2 (en) 2000-04-11 2001-10-18 University Of Southern California A METHOD TO PREVENT GRAFT REJECTION USING TGF-β TO INDUCE T SUPPRESSOR CELLS
AU2001296962A1 (en) 2000-09-29 2002-04-08 Schering Corporation Pegylated interleukin-10
FR2824567B1 (fr) * 2001-05-11 2003-08-08 Inst Nat Sante Rech Med Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene
WO2003074685A2 (en) * 2002-03-07 2003-09-12 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Il-10 gene transfer to peripheral blood mononuclear cells
GB0214528D0 (en) * 2002-06-24 2002-08-07 Univ Aberdeen Materials and methods for induction of immune tolerance
DK1565183T3 (da) 2002-11-29 2008-12-01 Maria Grazia Roncarolo Rapamycin og IL-10 til behandling af autoimmune sygdomme
FR2852967B1 (fr) * 2003-03-26 2007-12-07 Txcell Procede d'obtention de cellules dendritiques et de cellules t
FR2856700B1 (fr) * 2003-06-24 2007-06-08 Txcell Procede d'identification de lymphocytes tr1 regulateurs par la presence et la surexpression de molecules specifiques et ses applications
EP2591786B1 (en) 2003-10-16 2017-04-12 Cancure Limited Immunomodulating compositions and uses therefor
CA2545841A1 (en) * 2003-11-12 2005-05-26 Txcell Use of lipopeptides for activating t lymphocytes through the skin
JP4863452B2 (ja) * 2006-03-30 2012-01-25 国立大学法人 千葉大学 ヒトＴｈ１／Ｔｈ２分化誘導系及びその用途
CA2652148C (en) 2006-05-12 2016-10-04 Fondazione Centro San Raffaele Del Monte Tabor Tolerogenic dendritic cells, method for their production and uses thereof
US20120058096A1 (en) 2009-03-03 2012-03-08 St. Jude Children's Research Hospital Compositions and methods for generating interleukin-35-induced regulatory t cells
US10143778B2 (en) * 2010-12-21 2018-12-04 Cormatrix Cardiovascular, Inc Cardiovascular prostheses
EP3882337A1 (en) 2012-06-18 2021-09-22 Ospedale San Raffaele S.r.l. Compositions and methods for diminishing an immune response
CA2782942C (en) * 2012-07-12 2019-08-27 Canadian Blood Services Method for inducing immune tolerance using polymer-modified antigenic leukocytes
US11007221B2 (en) 2013-07-12 2021-05-18 Canadian Blood Services Acellular pro-inflammatory compositions, process for making same and methods of using same
KR101868950B1 (ko) 2017-05-18 2018-06-19 연세대학교 산학협력단 Ｉｌ－１０을 발현하는 신경줄기세포를 포함하는 중추 신경계 질환 또는 손상의 치료용 약학적 조성물 및 이를 이용한 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4483920A (en) 1982-05-17 1984-11-20 Hahnemann University Immobilization of message RNA directly from cells onto filter material
US4559310A (en) 1983-05-20 1985-12-17 Dana Farber Cancer Institute Assay methods and systems utilizing mast cell clones
IL94878A (en) 1989-06-28 2003-01-12 Schering Corp Cytokine synthesis inhibitory factor, antagonists thereof and methods of using same

Also Published As

Publication number Publication date
IL126658A0 (en) 1999-08-17
EP0906428A1 (en) 1999-04-07
WO1997042324A1 (en) 1997-11-13
ZA973815B (en) 1997-11-03
NO985160L (no) 1999-01-06
SK151898A3 (en) 2000-04-10
AU2927597A (en) 1997-11-26
BR9709307A (pt) 1999-08-10
CZ347798A3 (cs) 1999-03-17
NZ332413A (en) 2000-10-27
PL329732A1 (en) 1999-04-12
CA2253803A1 (en) 1997-11-13
KR20000010799A (ko) 2000-02-25
NO985160D0 (no) 1998-11-05
US6277635B1 (en) 2001-08-21
JP2000509604A (ja) 2000-08-02

Similar Documents

Publication Publication Date Title
AR006942A1 (es) Manufactura de un medicamento para inhibir una respuesta antigeno- especifica, composiciones farmaceuticas y celulas t anergicas antigeno-especificas
Duffner et al. Role of CXCR3-induced donor T-cell migration in acute GVHD
ECSP941104A (es) Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
ATE84032T1 (de) Benzimidazolderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische praeparate.
DE69620877D1 (de) Arzneimittelformulierungen für il-12
PH22556A (en) Heterocyclic compounds, pharmaceutical compositions containing the same and method of use thereof
BR9405798A (pt) Métodos para liberação in vivo de material biológico e composições úteis dos mesmos
AR004134A1 (es) Derivados 2-amino-6-anilino-purina y procedimiento y nuevos intermediarios para su preparacion, formulaciones farmaceuticas que comprenden talesderivados y el uso de estos derivados como medicamentos.
ES2058185T3 (es) Derivados de camptotecina y procedimiento para su preparacion.
ES2058411T3 (es) Sustancia fr 901228 y su preparacion.
ES2002089T3 (es) Nuevas formulaciones farmaceuticas con liberacion programada que contienen antiflogisticos.
ES2039278T3 (es) Procedimiento para preparar inhibidores de 5-alfa-reductasa de esteroides.
ES2111556T3 (es) Nuevas aminas alquil-heterociclicas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
CU22412A1 (es) Una mezcla natural compuesta por alcoholes alifaticos primarios superiores obtenidos de la cera de abejas para el tratamiento de las ulceras gastricas y duodenales que presenta tambien actividad antiinflamatoria
ATE9350T1 (de) Tricyclische cytosinderivate zur verwendung in arzneimitteln und verfahren zu ihrer herstellung.
ATE237331T1 (de) Deuterierte wirkstoffe in transdermaler applikation
MX9303572A (es) Inhibidores de proteasa del sindrome de inmunodeficiencia humana, procedimiento para su preparacion y formualcion farmaceutica que los contiene.
IT8867891A0 (it) Derivati terziobutilati di benzilidene canfora procedimento per la loro preparazione,loro impiego come agenti anti ossidanti e composizioni cosmetiche e farmaceutiche che li contengono
AR002972A1 (es) Pildoras que tienen una matriz farmaceutica que proporcionan un perfil apropiado de liberacion de la droga, composicion para la preparacion de dichamatriz, proceso para preparar dichas pildoras y formas de dosificacion de dicha composicion.
ATE3552T1 (de) Verfahren zur herstellung von phosphono-hydroxy- essigsaeure und salzen derselben sowie diese enthaltende autivirale mittel.
ATE85213T1 (de) Einen wirkstoff und ein in wasser quellendes polymer enthaltendes arzneimittel.
ES2053535T3 (es) Derivados heterociclicos de cinco miembros de n,n'-diacilhidrazinas n' sustituidas.
ES2054029T3 (es) Formulacion de acetato de flecainida con liberacion controlada.
DK0768896T3 (da) Lavdoserede steroidtabletter, der indeholder gallussyreestere som antioxidant, fremgangsmåde til fremstilling og anvendelse
ES2053679T3 (es) Embonato de azelastina, procedimiento para su preparacion y preparados farmaceuticos que contienen embonato de azelastina como principio activo.

Legal Events

Date Code Title Description
FB Suspension of granting procedure